|
TO BUSINESS AND MEDICAL EDITORS:
Integrated Pharmaceutical's Officers Adopt
Rule 10b5-1 Plans
FITCHBURG, Mass., Oct. 15 /PRNewswire/ --
Integrated Pharmaceuticals (INTP.PK) announced today that
three of its officers have adopted plans to sell common stock
of Integrated Pharmaceuticals pursuant to SEC rule 10b5-1.
That rule, promulgated under the Securities and Exchange Act
of 1934, allows persons who may be considered insiders to
establish written, pre-arranged stock trading plans when they
do not have material, non-public information about the company.
The plans establish predetermined trading parameters that
do not permit the person adopting the plan to exercise any
subsequent influence over how, when or whether to effect trades.
Under the plans as adopted, these officers may sell an aggregate
of 150,000 shares of IntePharm's common stock, which is less
than 3% of their total holding of shares, over the course
of several months. The officers having adopted the plans are
Chinmay Chatterjee, CEO, Edward Furtado, VP of Operations,
and Nilu Chatterjee, VP of R&D.
About the Company
IntePharm is a development stage biotechnology
company that seeks to discover and develop more efficient
and cost-effective ways to manufacture specialty pharmaceutical
products. IntePharm uses a comprehensive technology platform
that combines the application of metabolic engineering, cellular
genetics, advanced bioprocess engineering, and computer simulation
science for the development of efficient manufacturing programs
for recombinant proteins, small molecule therapeutics and
biopharmaceuticals for the treatment of degenerative, immunodeficiency,
and infectious diseases. The company has several market-ready
products in the pipeline that it plans to manufacture in the
near future.
For further information please contact Dr.
Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. at (978)
696-0020, or visit http://www.intepharm.com.
Forward-Looking Statements
Certain statements contained in this press
release that are not historical facts constitute "Forward-Looking
Statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements, in general,
predict, indicate or imply future results, performance or
achievements and generally use words so indicative. Such forward-looking
statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results or performance
of the Company and its business to be materially different
from that expressed or implied by such forward-looking statements.
Included in those factors are the following: general economic
and business conditions; sales and revenues mix; pricing levels;
changes in sales and revenues to, or the identity of significant
customers; changes in technology; industry capacity and production
rates; ability of outside third parties to comply with their
commitments; competition; capacity constraints; availability
of raw materials and adequate labor; availability of appropriate
professional expertise; and availability of liquidity sufficient
to meet the Company's needs. Forward-looking statements by
their very nature are uncertain. There can be no guarantee
that any forward-looking statement will be fulfilled. The
Company assumes no obligation to update forward-looking statements
to reflect actual results or changes in or additions to the
factors affecting such forward-looking statements.
SOURCE Integrated Pharmaceuticals, Inc.
Web Site: http://www.intepharm.com
Copyright © 1996-2004 PR Newswire Association
LLC. All Rights Reserved. A United Business Media company.
|
